Navigation Links
Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
Date:2/22/2010

rations: (1) To exclude amortization of commercial intangible assets related to marketed products. (2) To exclude upfront and milestone payments to partners. (3) To exclude purchased in-process research and development. (4) To exclude additional interest expense as a result of adopting ASC 470-20. (5) To exclude changes in fair value of financial instruments, net. (6) To reflect the tax effect of the pre-tax adjustments above at the applicable tax rates.

The following tables provide a reconciliation of our reported (GAAP) statements of operations to our adjusted statements of operations for each of the year ended Dec. 31, 2009 and Dec. 31, 2008 (Certain prior period amounts have been adjusted to reflect the retrospective adoption of accounting guidance pursuant to ASC 470-20: Debt With Conversion and Other Options (formerly referred to as FSP APB 14-1) and to conform to the current period presentation) (in thousands, except per share data):

    
    
    
                               Actual
    Year Ended Dec. 31,       Reported
     2009 (unaudited)          (GAAP)    Adjustments          Adjusted
                              --------   -----------          --------
    Total Revenues          $1,460,841             -        $1,460,841
    Costs and expenses:
      Cost of revenues         375,058       (74,199)   (1)    300,859
      Selling, general and
       administrative          534,523        (2,549)   (2)    531,974
      Research and
       development             185,317       (77,099)   (3)    108,218
      Impairment of
       intangibles              69,000       (69,000)   (4)          -
      Acqui
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014   Regulus Therapeutics Inc ... company leading the discovery and development of innovative ... its ATHENA natural history of disease study in ... disease with no approved therapy. The ATHENA study ... renal function markers such as Glomerular Filtration Rate ...
(Date:9/18/2014)... and ROCKVILLE, Md. , ... SPPI ), a biotechnology company with fully integrated ... in hematology and oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ...
(Date:9/18/2014)... Sept. 18, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that the Company,s ... Geert Cauwenbergh , will present at the ... on Wednesday, September 24, 2014 at 11:20 ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... 2011 On Sunday, August 21, veterinary cardiologists are ... the Mobile Dog Heart Health Tour will stop with ... examinations at Peters Park Dog Run. (Photo: ... free heart health screenings, veterinarians will be available to ...
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... it has finalized a previously disclosed Equipment Financing ... $10 million in available funding. This agreement will ... finance the automated assembly line now manufacturing the ...
Cached Medicine Technology:Free Dog Heart Health Screenings Available August 21 in Boston 2Unilife Signs $10 Million Equipment Financing Agreement 2Unilife Signs $10 Million Equipment Financing Agreement 3Unilife Signs $10 Million Equipment Financing Agreement 4
(Date:9/18/2014)... Qualis Health, one of the nation’s leading population ... “Advancing Primary Care through the Patient-Centered Medical Home Model ... Jeff Hummel, MD, MPH and Peggy C. Evans, PhD, ... the work of becoming a Patient-Centered Medical Home (PCMH) ... such as generating and providing useful data that can ...
(Date:9/18/2014)... developed a new method to study Ebola virus in ... Conservation Society (WCS)-led research, published today in the journal ... of fecal samples from wild great apes to identify ... This represents a new tool for performing large, population-scale ... virus is studied and improve our understanding of the ...
(Date:9/18/2014)... recommending that elderly men should not be routinely screened ... to a new study led by researchers at Henry ... online in JAMA Internal Medicine , focused on ... test for prostate cancer., "We found that the effect ... elderly men in particular has been minimal at best," ...
(Date:9/18/2014)... 2014 With the swift industrial development ... such as smart phones, tablets and PDAs, a complete ... mobile devices are viewed these days. From only being ... becoming a mode for creating and delivering content while ... way. , The complete makeover of this ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 A sold-out ... community advocates, and volunteers supported United Way of ... Chefs and Fine Wines” event Monday, Sept. 15. Proceeds ... health initiatives in Westchester and Putnam, such as providing ... steering teens away from risky behaviors like drug and ...
Breaking Medicine News(10 mins):Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Transparency Market Research: M-health Market Study 2018 2Health News:Transparency Market Research: M-health Market Study 2018 3Health News:Transparency Market Research: M-health Market Study 2018 4Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 2Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 3
... people who have optic nerve damage might be at ... the study researchers involved 25 people with visual impairment. ... days, and their results were compared with those of ... that those with optic nerve disease were 20-times more ...
... inflammation of the liver and can cause complications such ... the hepatitis B vaccine is recommended for infants. Previous ... against infection for up to 10 years. However, a ... 10 years. ,Researchers followed eight-hundred-and-forty-one Alaska natives vaccinated ...
... of the expectant mother. Now a new study suggests ... of preeclampsia in the pregnant women. ,The ... with periodontitis with atherosclerosis to preeclampsia. Such an oral ... abuse like smoking, etc. The basic reason for setting ...
... and vitamin B12 are safe and effective in reducing the ... a stroke . According to researchers stroke patients have a ... healthy peers due to higher levels of plasma homocysteine in ... of hip fracture. ,The study was initiated to ...
... in Japan, even after the country has banned the shots of ... of the must-have vaccines to be given to children before they ... journal Lancet in 1998 had published a paper relating the MMR ... there had been considerable fall in vaccinating children with MMR (Measles, ...
... benefits of alcohol consumption and cardiovascular disease researchers studied ... // moderate levels of alcohol (one to seven drinks ... eight drinks per week), and did not consume any ... first to focus on the association between alcohol intake ...
Cached Medicine News:
Caspar Curette, 250 mm, 10"....
Bone Curette, 160 mm...
Bone Curette, 145 mm...
Bone Currettes...
Medicine Products: